Physician profile
Julie A Craft
NPI 1295402303
$2,164.54
in general payments reported to CMS, 2019-2025
22 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what 96% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $901 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,164.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $333.80 | 2024-2025 | Ingrezza |
| Sk Life Science, INC. | $214.22 | 2024-2025 | Xcopri |
| Emd Serono, INC. | $187.43 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $164.82 | 2024-2025 | Hyqvia |
| Abbvie INC. | $159.71 | 2024-2025 | |
| Ucb, INC. | $152.47 | 2025 | Fintepla |
| Biogen, INC. | $148.92 | 2024-2025 | Vumerity, Leqembi |
| Alexion Pharmaceuticals, INC. | $117.85 | 2024-2025 | Ultomiris |
| Tg Therapeutics, INC. | $97.74 | 2024-2025 | |
| Neurelis, INC. | $93.99 | 2024-2025 | Valtoco |
| Novartis Pharmaceuticals Corporation | $86.03 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $70.80 | 2024 | Zeposia |
| Genzyme Corporation | $68.76 | 2025 | |
| Eisai INC. | $52.35 | 2024-2025 | |
| Celgene Corporation | $51.90 | 2025 | Zeposia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $27.59 | 2024 | Nuplazid |
| Banner Life Sciences, LLC | $25.73 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $24.05 | 2025 | Ajovy |
| Pfizer INC. | $23.21 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $22.92 | 2025 | Lumryz |
| Amgen INC. | $22.80 | 2024 | Uplizna |
| Tanabe Pharma America, INC. | $17.45 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Craft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.